期刊文献+

阿司匹林对口腔NNIS 0级手术术后出血影响的Meta分析

The effect of aspirin on postoperative bleeding in patients undergoing oral NNIS 0 stage surgery A Meta-Analysis
下载PDF
导出
摘要 目的:用循证医学的方法来评估单独口服阿司匹林的患者对口腔NNIS 0级手术术后出血情况的影响。方法:检索Pubmed及万方数据库,收集并筛选2007年1月1日至2016年12月31日期间的关于阿司匹林对口腔NNIS 0级术后出血情况影响的临床试验,并进行Meta分析。结果:共检索出98篇文献,经过筛选对纳入的5项研究进行Meta分析发现,口腔NNIS 0级手术前不停用阿司匹林对患者术后30min的出血情况无显著影响(相对危险度(odds ratio,OR)=1.23,95%可信区间(confidence interval,CI):0.90-1.68,p=0.211)。结论:低剂量(≤150mg/d)口服阿司匹林患者在口腔NNIS 0级手术前不需要停用药物。 Objective: To evaluate bleeding status of oral surgery with National Nosocomial Infection Surveillance risk index of 0 (NNIS 0) in patients on oral anticoagulated aspirin therapy using meta-analysis system. Methods: The PubMed and Wanfang databases were searched. Eligible studies were randomized controlled trials (RCTs) and controlled clinical trials on postoperative hemorrhage of continuation of aspirin before oral NNIS 0 surgery published from January 1, 2007 to December 31, 2016. Results: A total of 98 articles were retrieved and five studies were included in meta-analysis. The results showed no significant difference between patients on aspirin therapy and no oral anticoagulated therapy when postoperative bleeding were observed at 30 minutes (OR=1.23, 95%CI: 0.90-1.68, p=0.221). Conclusions: We recommend not stopping use aspirin (~〈 150mg/d) before oral NNIS 0 surgery.
出处 《中华老年口腔医学杂志》 2017年第4期228-230,247,共4页 Chinese Journal of Geriatric Dentistry
基金 上海市科学技术委员会基金资助(项目编号:15ZR1424700) 国家自然科学基金(项目编号:81671036)
关键词 阿司匹林 循证医学 口腔NNIS 0级手术 术后出血 aspirin evidence-based medicine oral NN1S 0 surgery postoperative hemorrhage
  • 相关文献

参考文献5

二级参考文献26

  • 1郭继鸿,许俊堂.冠心病介入治疗围手术期的抗凝治疗[J].中国实用内科杂志,2005,25(1):5-7. 被引量:21
  • 2Jeske AH, Suchko GD. Lack of a scientific basis for routine discontinuation of or anticoagulation therapy before dental treatment. J Am Dent Assoc,2003,134 ( ! 1 ) : 1492-1497.
  • 3Brennan MT, Valerin MA, Noll JL, et al. Aspirin use and post-operative bleeding from dental extractions. J Dent Res,2008, 87 ( 8 ) :740-744.
  • 4Moher D. Cook DJ. Eastwood S. et al. Improving the quality of reports of Meta-analyses of randomized controlled trials: the QUOROM statement [J] . Lancet.1999,354:1896-1900.
  • 5Moher D. Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and Metaanalyses: the PRISMA statement [J] . Ann Intern Med.2009,151:264-269.
  • 6Bagshaw SM. Mcalister FA. Manns BJ, et al. Acetylcysteine in the prevention of contrast-induced nephropathy: a case study of the pitfalls in the evolution of evidence[J]. Arch Inter Med, 2006, 116 : 161-166.
  • 7Biondi GC, Lotrionte M, Abbate A. et al. Compliance with QUOROM and quelity of reports of overlapping Meta analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: Case study [J] . BMJ. 2006. 322: 202- 209.
  • 8Harrison P,Frelinger III AL,Furman MI,et al.Measuring antiplatelet drug effects in the laboratory[J].Thrombosis re- search, 2007,120(3 ) : 323-336.
  • 9Ugurlucan M, Caglar IN, Caglar FN, et al.Aspirin:from a his- torical perspective[ J ].Recent patents on cardiovascular drug discovery, 2012,7 ( 1 ) : 71-76.
  • 10Hall R, Mazer CD.Antiplatelet drugs:a review of their phar- macology and management in the perioperative period[J]. Anesthesia & Analgesia, 2011,112(2) : 292-318.

共引文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部